Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-15,023
Closed -$1.72M 243
2024
Q3
$1.72M Sell
15,023
-155
-1% -$14K 0.07% 104
2024
Q2
$1.15M Sell
15,178
-975
-6% -$66.4K 0.05% 119
2024
Q1
$1.1M Sell
16,153
-5,156
-24% -$357K 0.05% 127
2023
Q4
$1.34M Buy
21,309
+143
+0.7% +$7.43K 0.07% 108
2023
Q3
$1.08M Buy
21,166
+1,592
+8% +$78.5K 0.06% 124
2023
Q2
$978K Buy
+19,574
New +$928K 0.05% 135

Other funds holding PCVX

Bank of Hawaii's PCVX Position: Q4 2024 in Review

Bank of Hawaii sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 15,023 shares — an estimated $1.72M sold.

Bank of Hawaii first reported a position in PCVX in Q2 2023 and held it in 6 quarters. The position peaked at $1.72M in Q3 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • Bank of Hawaii reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • Bank of Hawaii sold 15,023 Vaxcyte shares in Q4 2024, an estimated $1.72M.
  • Bank of Hawaii first reported a position in Vaxcyte in Q2 2023 and held it in 6 quarters.
  • Bank of Hawaii's Vaxcyte position peaked at $1.72M in Q3 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Bank of Hawaii's 13F filing for Q4 2024, filed 13 Feb 2025.